BPC-157 + GHK-Cu + TB-500 + Collagen Peptides Wound Care Stack

The standard healing stack (BPC-157 + TB-500) is designed for musculoskeletal injuries. This wound care stack adds GHK-Cu for collagen quality and extracellular matrix remodeling — critical in skin and soft tissue wounds — and collagen peptides as substrate. Wound healing involves skin, subcutaneous tissue, and often fascia, which have different biological requirements than tendon or muscle repair. The topical application of GHK-Cu directly to wound surfaces is also unique to this protocol.

GHK-Cu has been shown to accelerate wound closure in animal models when applied topically. For open wounds, use only medical-grade, sterile preparations — standard cosmetic GHK-Cu serums are not sterile and risk introducing infection. Apply to clean, non-infected wound beds after initial hemostasis. Avoid application to actively bleeding wounds or wounds with signs of infection (increased redness, warmth, purulent discharge). Once the wound has an epithelial cover (even if fragile), standard topical preparations become appropriate.

Oral collagen peptides are hydrolyzed and absorbed as dipeptides and tripeptides (primarily hydroxyproline-glycine and hydroxyproline-proline-glycine). These specific peptide fragments are not fully degraded to free amino acids — they circulate intact and have been shown to accumulate in skin tissue. There, they serve dual roles: as building blocks for collagen synthesis and as signaling molecules that stimulate fibroblast activity and collagen production. Multiple randomized controlled trials confirm improved skin elasticity and wound healing parameters with oral collagen supplementation.

Surgical incisions, skin lacerations, abrasions, skin grafts, and chronic non-healing wounds (diabetic ulcers, venous stasis ulcers) are the primary applications. Post-surgical wounds with adequate closure benefit from accelerated healing and reduced scar formation. Chronic wounds that have stalled in the inflammatory phase may restart their healing trajectory. Burns — particularly partial-thickness — are another application, though severe burns require specialized medical management beyond peptide protocols.

Yes. Vitamin C (ascorbic acid) is an essential cofactor for prolyl hydroxylase and lysyl hydroxylase — enzymes that hydroxylate proline and lysine residues in collagen, which is necessary for proper collagen cross-linking and structural integrity. Without adequate vitamin C, collagen synthesis is impaired regardless of peptide stimulation or substrate availability. A minimum of 500 mg daily is recommended; some protocols use 1,000–2,000 mg daily during active wound healing. This is one of the most evidence-based adjuncts to any wound healing protocol.

GHK-Cu is the scar-minimization component. It remodels collagen from disorganized scar tissue toward normal architecture by activating both collagen synthesis and controlled collagen degradation via metalloproteinases. Continue GHK-Cu topical application for 4–8 weeks after wound closure to influence the remodeling phase. BPC-157 may also reduce scar formation by promoting more organized healing rather than fibrotic repair. Silicone sheeting or gel can be added once the wound is fully closed. Early mobilization and appropriate mechanical stress on the healing tissue also reduce scar contracture.

Many practitioners use BPC-157 + TB-500 post-surgically, and the addition of GHK-Cu and collagen peptides targets the skin and soft tissue component of surgical recovery specifically. Wait until initial wound closure is stable (typically 3–7 days post-surgery) before starting injectable peptides near the surgical site. Topical GHK-Cu can be applied to the closed incision line once sutures or staples are removed. Discuss with your surgeon before adding any intervention — some surgeons have specific recovery protocols they prefer patients follow.

Chronic wounds (present for more than 4–6 weeks without healing progress) are often stuck in a prolonged inflammatory phase with elevated matrix metalloproteinase activity, bacterial biofilm, and senescent fibroblasts. This stack addresses several of these issues: BPC-157 provides anti-inflammatory and angiogenic signaling, GHK-Cu rebalances matrix metalloproteinase activity, TB-500 stimulates new cell migration into the wound bed, and collagen peptides provide substrate. However, underlying causes (diabetes, vascular insufficiency, infection, nutritional deficiency) must be addressed concurrently — peptides cannot overcome systemic pathology.

Avoid using this stack on actively infected wounds — infection must be controlled with appropriate antimicrobials before introducing regenerative peptides. Malignant wounds (arising from or invaded by cancer) should not be treated with growth-promoting peptides, as they could theoretically accelerate tumor growth. Wounds from animal bites or heavily contaminated injuries require tetanus prophylaxis and sometimes rabies assessment — peptide protocols should not delay appropriate emergency care. Full-thickness burns covering large body surface areas require specialized burn center management.